Steward Partners Investment Advisory’s Lineage Cell Therapeutics LCTX Stock Holding History

Steward Partners Investment Advisory’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.98K	Buy	3,800 +2,500	+192%	+$3.46K	﹤0.01%	3976
2026 Q1	$2.05K	Buy	+1,300	New	+$2.19K	﹤0.01%	4045
2025 Q4	–	Sell	-11	Closed	-$19	–	4407
2025 Q3	$19	Buy	+11	New	+$13	﹤0.01%	4233
2018 Q4	–	Sell	-1,143	Closed	-$2K	–	1529
2018 Q3	$2K	Hold	1,143	–	–	﹤0.01%	2379
2018 Q2	$2K	Hold	1,143	–	–	﹤0.01%	2226
2018 Q1	$2K	Hold	1,143	–	–	﹤0.01%	2012
2017 Q4	$2K	Buy	+1,143	New	+$2.5K	﹤0.01%	1702

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Steward Partners Investment Advisory's LCTX Position: Q2 2026 in Review

Steward Partners Investment Advisory increased its Lineage Cell Therapeutics (LCTX) stake by 192% in Q2 2026, buying an estimated $3.46K and bringing the position to 3,800 shares worth $4.98K. The position accounts for ﹤0.01% of the portfolio, ranked #3976.

Steward Partners Investment Advisory first reported a position in LCTX in Q4 2017 and has held it in 7 quarters since. 126 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Steward Partners Investment Advisory held 3,800 shares of Lineage Cell Therapeutics worth $4.98K as of Q2 2026.
Steward Partners Investment Advisory bought 2,500 Lineage Cell Therapeutics shares in Q2 2026, an estimated $3.46K.
Lineage Cell Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3976 holding.
Steward Partners Investment Advisory first reported a position in Lineage Cell Therapeutics in Q4 2017 and has held it in 7 quarters since.
126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.